CareQuest and Henry Schein Put HbA1c Screening Into Dental Hygiene Workflows
CareQuest Institute for Oral Health and Henry Schein have launched the BRIDGE Health Network, a nine-organization pilot designed to move medical screening into routine dental hygiene visits.
Researching dental technology?
Compare 1092+ dental vendors by category, use case, integrations, and fit.
Participating teams will collect vital signs and lifestyle markers and use CLIA-waived point-of-care tests, including HbA1c screening. Practices will give patients a systemic-health summary, educational resources and support with medical follow-up when screening identifies a potential risk.
The announcement is more consequential than another oral-systemic-health partnership. It adds implementation infrastructure: clinical workflows, testing supplies, staff training, practice-management fields and a defined group of pilot sites.
What the first pilots include
The inaugural cohort spans community providers, multi-site dental groups and dental schools:
- Bright Direction Dental
- Imagine Medical & Dental Group
- NKC Dental
- Smile House JBL
- University of Pennsylvania School of Dental Medicine
- University of Pittsburgh School of Dental Medicine
- Workman School of Dental Medicine at High Point University
- Westwind Integrative Health
- Zufall Health
Henry Schein will lead implementation, distribute devices and supplies, provide technical support and train participating clinics. CareQuest will provide program-level data support and work with the clinical partners on the initiative.
The parties say the pilots are intended to answer three practical questions: whether the workflows are clinically useful, whether practices can execute them consistently and whether the model has a sustainable financial and operational case.
That last question is critical. The announcement does not disclose a budget, target patient volume, pilot duration, reimbursement model or expected practice revenue. BRIDGE is a structured test, not yet evidence that chairside medical screening can scale commercially.
Dental software becomes part of the screening workflow
Henry Schein One has added fields to Dentrix Ascend so participating practices can capture point-of-care screening data inside the dental record. The announcement also says results can be recorded in Axium.
That is a meaningful product decision. A screening program that lives on paper or in a separate portal creates another disconnected task for hygienists and front-office teams. Putting results inside the clinical workflow makes adoption more plausible and creates a base for reporting, follow-up and eventual interoperability.
It does not, by itself, connect the dental record to a medical EHR. The pilots still need to demonstrate how an abnormal result reaches the patient's medical provider, how consent and data-sharing are handled and whether follow-up actually occurs.
The initiative extends the same market direction highlighted in Avized's analysis of Toothsome's employer-funded dental model: dental technology is moving beyond isolated practice transactions toward broader health, benefit and care-coordination infrastructure.
Why the business case matters
Dental offices offer access to patients who may not regularly see a primary-care clinician. The announcement cites research indicating that chairside HbA1c screening can identify elevated results among patients who were not previously diagnosed with diabetes or prediabetes.
But clinical opportunity does not automatically create an operating model.
A scalable program needs to answer who pays for the test, how staff time is compensated, whether screening slows hygiene capacity, how positive results are documented and referred and whether practices receive credit for closing a medical care gap.
This is the same evidence standard discussed in Avized's analysis of dental's next value-creation cycle: a promising workflow becomes valuable when it produces measurable clinical or operating performance, not when it merely expands the feature set.
Payers may eventually have the strongest reason to fund these workflows if earlier detection reduces downstream medical costs. Employers, accountable-care organizations and medical groups could also become buyers. The pilots need to show which party receives enough measurable value to support the program after initial sponsorship.
The data layer could become the strategic asset
BRIDGE is initially framed around screening, but the more durable asset may be the workflow and data infrastructure it creates.
Standardized screening results across dental sites could support referral tracking, care-gap reporting and risk identification. If those data can move reliably between dental software, medical systems and payer programs, the dental visit becomes a new input into population-health operations.
That mirrors the carrier-side automation described in Avized's analysis of Guardian's AI benefit-verification program. Both initiatives treat dental interactions as structured infrastructure rather than isolated office activity—one for clinical risk, the other for benefits administration.
The risk is that each organization creates another closed data workflow. BRIDGE will matter more if its playbook includes practical standards for consent, referral completion, record exchange and outcome measurement.
What to watch next
Workflow burden. The pilots should report how much time screening adds to a hygiene visit and which team members own testing, education and follow-up.
Patient follow-through. Identifying elevated HbA1c is useful only if patients reach appropriate medical care and the dental team can confirm the handoff.
Economics. Watch for a disclosed reimbursement, sponsorship or shared-savings model that makes screening sustainable after the pilot.
Software integration. New record fields are a starting point. The larger test is whether results move into medical and payer workflows without duplicate entry.
Measured outcomes. The strongest evidence would include screening volume, abnormal-result rates, completed referrals, patient acceptance and the operating cost per completed intervention.
Expansion beyond diabetes. The announcement refers to vital signs and lifestyle markers in addition to HbA1c. Future pilots may test other conditions where dental visits create a practical screening opportunity.
BRIDGE gives dental-medical integration something it often lacks: a defined implementation structure. The market signal will depend on whether the first cohort converts that structure into repeatable workflows, measurable outcomes and a buyer willing to fund the model.
Primary sources
- CareQuest and Henry Schein — BRIDGE Health Network announcement, November 10, 2026
- CareQuest Institute — BRIDGE Health Network program description
Program details and cited screening figures are attributed to the participating organizations. Avized's market and operating implications are independent editorial analysis.
Related resources
Avized Weekly
Get this kind of analysis every Wednesday.
Independent dental vendor intel — new profiles, comparisons, and market trends.
Browse the full dental AI database
1092 vendors profiled, compared, and ranked by data — not marketing spend.
Browse vendors